90 research outputs found
A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD
<p>Abstract</p> <p>Background</p> <p>NS2359 is a potent reuptake blocker of noradrenalin, dopamine, and serotonin. The aim of the study was to investigate the efficacy, safety and cognitive function of NS2359 in adults with a DSM IV diagnosis of ADHD.</p> <p>Methods</p> <p>The study was a multi-centre, double-blind, randomized placebo-controlled, parallel group design in outpatient adults (18â55 years) testing 0.5 mg NS2359 vs. placebo for 8 weeks. Multiple assessments including computerized neuropsychological evaluation were performed.</p> <p>Results</p> <p>There was no significant difference between NS2359 (n = 63) versus placebo (n = 63) on the primary outcome measure reduction in investigator rated ADHD-RS total score (7.8 versus 6.4; p < 0.45). However, in subjects with the inattentive subtype, there were significantly more responders in the NS2359 group compared to placebo (41% versus 7%; p < 0.01). For all secondary variables (ADHD-RS patient rated; The Conners Adult ADHD Scale; The Brown Adult Scale, and CGI-improvement scale) there were no significant differences between the two groups; however, in the inattentive subgroup, the response to treatment was significantly larger than to placebo. NS2359 improved composite factor scores of attention, episodic- and working memory. No serious adverse events were reported with insomnia, headaches and loss of appetite most commonly reported as side effects.</p> <p>Conclusion</p> <p>No overall effect of NS2359 was found on overall symptoms of ADHD. There was also a modest signal of improvement in the inattentive adults with ADHD and cognition warranting further exploration using differing doses.</p
Bacille Calmette-GuĂŠrin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial
Contains fulltext :
169904.pdf (publisher's version ) (Open Access)INTRODUCTION: BCG vaccination has been associated with beneficial non-specific effects on child health. Some immunological studies have reported heterologous effects of vaccines on antibody responses to heterologous vaccines. Within a randomised clinical trial of Bacille Calmette-Guerin (BCG) vaccination at birth, The Danish Calmette Study, we investigated the effect of BCG at birth on the antibody response to the three routine vaccines against DiTeKiPol/Act-Hib and Prevenar 13 in a subgroup of participants. METHODS: Within 7days after birth, children were randomised 1:1 to BCG vaccination or to the control group (no intervention). After three routine vaccinations given at age 3, 5 and 12months, antibodies against DiTeKiPol/Act-Hib and Prevenar 13 (Streptococcus pneumoniae serotype type 4, 6B, 9V, 14, 18C, 19F and 23F) were measured 4weeks after the third vaccine dose. RESULTS: Among the 300 included children (178 BCG; 122 controls), almost all children (>96%) had antibody responses above the protective levels. Overall BCG vaccination at birth did not affect the antibody level. When stratifying by 'age at randomisation' we found a possible inducing effect of BCG on antibodies against B. pertussis and all pneumococcal serotypes, when BCG was given after the first day of life. Girls had significantly higher antibody levels for Haemophilus influenza type b and pneumococcus than boys. CONCLUSIONS AND RELEVANCE: Three routine vaccinations with DiTeKiPol/Act-Hib and Prevenar 13 induced sero-protective levels in almost all children. No overall effect of neonatal BCG vaccination was observed
Fabrication of a Silicide Thermoelectric Module Employing Fractional Factorial Design Principles
publishedVersionPaid Open AccessUNIT agreemen
Adverse reactions to the Bacillus Calmette-GuĂŠrin (BCG) vaccine in new-born infants:an evaluation of the Danish strain 1331 SSI in a randomized clinical trial
AbstractObjectiveTo evaluate adverse reactions of the Bacillus CalmetteâGuĂŠrin (BCG) Statens Serum Institut (SSI) (Danish strain 1331) used as intervention in a randomized clinical trial.DesignA randomized clinical multicenter trial, The Danish Calmette Study, randomizing newborns to BCG or no intervention. Follow-up until 13 months of age.SettingPediatric and maternity wards at three Danish university hospitals.ParticipantsAll women planning to give birth at the three study sites (n=16,521) during the recruitment period were invited to participate in the study. Four thousand one hundred and eighty four families consented to participate and 4262 children, gestational age 32 weeks and above, were randomized: 2129 to BCG vaccine and 2133 to no vaccine. None of the participants withdrew because of adverse reactions.Main outcome and measureTrial-registered adverse reactions after BCG vaccination at birth. Follow-up at 3 and 13 months by telephone interviews and clinical examinations.ResultsAmong the 2118 BCG-vaccinated children we registered no cases of severe unexpected adverse reaction related to BCG vaccination and no cases of disseminated BCG disease. Two cases of regional lymphadenitis were hospitalized and thus classified as serious adverse reactions related to BCG. The most severe adverse reactions were 10 cases of suppurative lymphadenitis. This was nearly a fivefold increase compared to what was expected based on the summary of product characteristics of the vaccine. All cases were treated conservatively and recovered. Six of 10 (60%) families of children experiencing suppurative lymphadenitis compared to 117/2071 (6%) of those with no lymphadenitis indicated that the vaccine had more adverse effects than expected (p-value <0.001).Conclusions and relevanceBCG vaccination was associated with only mild morbidity and no mortality. A higher incidence of suppurative lymphadenitis than expected was observed. All children were treated conservatively without sequelae or complications.Trial registrationTrial registration number NCT01694108 at www.clinicaltrials.go
BCG vaccination at birth and early childhood hospitalisation:a randomised clinical multicentre trial
BACKGROUND: The BCG vaccine is administered to protect against tuberculosis, but studies suggest there may also be non-specific beneficial effects upon the infant immune system, reducing early non-targeted infections and atopic diseases. The present randomised trial tested the hypothesis that BCG vaccination at birth would reduce early childhood hospitalisation in Denmark, a high-income setting. METHODS: Pregnant women planning to give birth at three Danish hospitals were invited to participate. After parental consent, newborn children were allocated to BCG or no intervention within 7â
days of age. Randomisation was stratified by prematurity. The primary study outcome was number of all-cause hospitalisations analysed as repeated events. Hospitalisations were identified using The Danish National Patient Register. Data were analysed by Cox proportional hazards models in intention-to-treat and per-protocol analyses. RESULTS: 4184 pregnant women were randomised and their 4262 children allocated to BCG or no intervention. There was no difference in risk of hospitalisation up to 15â
months of age; 2129 children randomised to BCG experienced 1047 hospitalisations with a mean of 0.49 hospitalisation per child compared with 1003 hospitalisations among 2133 control children (mean 0.47), resulting in a HR comparing BCG versus no BCG of 1.05 (95% CI 0.93 to 1.18) (intention-to-treat analysis). The effect of BCG was the same in children born at term (1.05 (0.92 to 1.18)) and prematurely (1.07 (0.63 to 1.81), p=0.94). The effect was also similar in the two sexes and across study sites. The results were essentially identical in the per-protocol analysis and after adjustment for baseline characteristics. CONCLUSIONS: BCG vaccination at birth did not reduce the risk of hospitalisation for somatic acquired disease until 15â
months of age in this Danish study population. TRIAL REGISTRATION NUMBER: NCT01694108, results
Myocardial Work in Patients Hospitalized With COVIDâ19:Relation to Biomarkers, COVIDâ19 Severity, and AllâCause Mortality
BACKGROUND: COVIDâ19 infection has been hypothesized to affect left ventricular function; however, the underlying mechanisms and the association to clinical outcome are not understood. The global work index (GWI) is a novel echocardiographic measure of systolic function that may offer insights on cardiac dysfunction in COVIDâ19. We hypothesized that GWI was associated with disease severity and allâcause death in patients with COVIDâ19. METHODS AND RESULTS: In a multicenter study of patients admitted with COVIDâ19 (n=305), 249 underwent pressureâstrain loop analyses to quantify GWI at a median time of 4âdays after admission. We examined the association of GWI to cardiac biomarkers (troponin and NTâproBNP [Nâterminal proâBâtype natriuretic peptide]), disease severity (oxygen requirement and CRP [Câreactive protein]), and allâcause death. Patients with elevated troponin (n=71) exhibited significantly reduced GWI (1508 versus 1707âmmâHg%; P=0.018). A curvilinear association to NTâproBNP was observed, with increasing NTâproBNP once GWI decreased below 1446âmmâHg%. Moreover, GWI was significantly associated with a higher oxygen requirement (relative increase of 6% per 100âmmâHg% decrease). No association was observed with CRP. Of the 249 patients, 37 died during followâup (median, 58âdays). In multivariable Cox regression, GWI was associated with allâcause death (hazard ratio, 1.08 [95% CI, 1.01â1.15], per 100âmmâHg% decrease), but did not increase Câstatistics when added to clinical parameters. CONCLUSIONS: In patients admitted with COVIDâ19, our findings indicate that NTâproBNP and troponin may be associated with lower GWI, whereas CRP is not. GWI was independently associated with allâcause death, but did not provide prognostic information beyond readily available clinical parameters. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04377035
Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients:the ECHOVID-19 study
The association between Bacillus Calmette-GuĂŠrin vaccination (1331 SSI) skin reaction and subsequent scar development in infants
Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia
- âŚ